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Buccal delivery of drugs provides an attractive alternative to the oral route of drug
administration, particularly in overcoming deficiencies associated with the latter mode
of administration. Problems such as high first-pass metabolism and drug degradation in
the harsh gastrointestinal environment can be circumvented by administering the drug
via the buccal route (1–3). Moreover, buccal drug absorption can be promptly terminat-
ed in case of toxicity by removing the dosage form from the buccal cavity. It is also pos-
sible to administer drugs to patients who cannot be dosed orally to prevent accidental
swallowing. Therefore adhesive mucosal dosage forms were suggested for oral delivery,
which included adhesive tablets (4–6), adhesive gels (7, 8) and adhesive patches (9, 10).
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Buccoadhesive tablets of carvedilol were prepared using
HPMC K4M, HPMC K15M and Carbopol 934 as muco-
adhesive polymers. Fifteen formulations were develop-
ed with varying concentrations of polymers. Formulati-
ons of the BC or BD series were composed of HPMC K4M
or HPMC K15M in ratios of 1:1 to 1:5 whereas in the BE
series Carbopol 934 was used (1:0.25 to 1:1.50). The for-
mulations were tested for in vitro drug release, in vitro
bioadhesion, moisture absorption and in vitro drug per-
meation through porcine buccal mucosa. Formulation BC3
showed maximum release of the drug (88.7 ± 0.4%) with
the Higuchi model release profile and permeated 21.5 ±
2.9% of the drug (flux 8.35 ± 0.291 µg h–1cm–2) perme-
ation coefficient 1.34 ± 0.05 cm h–1) through porcine buc-
cal membrane. BC3 formulation showed 1.62 ± 0.15 N of
peak detachment force and 0.24 ± 0.11 mJ of work of ad-
hesion. FTIR results showed no evidence of interaction
between the drug and polymers. XRD study revealed that
the drug is in crystalline form in the polymer matrix. The
results indicate that suitable bioadhesive buccal tablets
with desired permeability could be prepared.
Keywords: buccal tablets, carvedilol, formulation, bioad-
hesion, evaluation
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Carvedilol is a non-selective b-adrenergic antagonist used in the treatment of hyper-
tension and stable angina pectoris. It also possesses antioxidant and antiproliferative ef-
fects, which may enhance its ability to combat the deleterious effects of sympathetic ner-
vous system activation in heart failure (11). Carvedilol was selected as a model drug for
the investigation because its oral dose is low (6.25–25 mg) (12). A suitable buccal drug
delivery system should possess good bioadhesive properties, so that it can be retained in
the oral cavity for the desired duration. In addition, it should release the drug in a pre-
dictable manner to elicit the required therapeutic response.
In our previous report (13), buccal patches of carvedilol released the drug for 5 h. To
prolong the drug release and to reduce dosing frequency, a suitable formulation was re-
quired with a controlled rate to treat hypertension. In the present study, buccoadhesive
tablets were developed using a hydrophilic polymer, hydroxypropyl methylcellulose
(HPMC K4M and K15M) and Carbopol 934 to get controlled and zero order release.
EXPERIMENTAL
Materials
Carvedilol was donated by Sun-Pharmaceuticals, India, hydroxypropyl methylcel-
lulose (Methocel K4M, Methocel K15M) by Colorcon Asia, India, Carbopol 934 (Noveon,
Inc., USA.) and Perlitol SD 200 (Roquette, USA) by Zydus Cadila, India. All other chemi-
cals and reagents used were of analytical grade and purchased from Merck Ltd., India.
Buccoadhesive tablets preparation
Carvedilol was mixed manually in glass bottles with different ratios of Methocel K4M
and K15M, Carbopol 934 as mucoadhesive polymers and Pearlitol S.D 200 (mannitol) as
diluent (Table I) for 10 min. The blend was lubricated with sodium stearyl fumarate (SSF)
for 3–5 min and then compressed into tablets by the direct compression method using
8-mm flat-faced punches. The tablets were compressed using a Cadmach rotary tablet
machine (Cadmach Machinery, India). The mass of the tablets were determined using a
digital balance (Shimadzu Japan) and thickness with a digital screw gauge (Mitatyo, Japan).
Assay of carvedilol
Twenty tablets were taken and powdered; powder equivalent to one tablet was tak-
en and was allowed to dissolve in 100 mL of 0.5% (m/V) of sodium lauryl sulphate solu-
tion on a rotary shaker overnight. The solution was centrifuged and the supernatant was
collected. The absorbance was measured using a UV-Vis Spectrophotometer (Elico, India) at
244 nm.
In vitro release studies
The drug release rate from buccal tablets was studied using the USP 28 (14) type II
dissolution test apparatus (Lab India dissolution test apparatus Disso 2000) equipped
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with an auto sampler and fraction collector for the collection and replenishment of the
sample and dissolution medium, respectively. Tablets were supposed to release the drug
from one side only; therefore an impermeable backing membrane was placed on the
other side of the tablet. The tablet was further fixed to a 2x2 cm glass slide with a solu-
tion of cyanoacrylate adhesive. Then it was placed in the dissolution apparatus. The dis-
solution medium was 500 mL of 0.5% (m/V) of sodium lauryl sulphate solution at 50
rpm at a temperature of 37 ± 0.5 °C. Samples of 5 mL were collected at different time in-
tervals up to 8 h and analyzed spectrophotometrically.
Tissue isolation
Porcine buccal tissue from domestic pigs was obtained from a local slaughterhouse
and used within 2 hours of slaughter. The tissue was stored in Krebs buffer pH 7.4 at 4 °C
after collection. The epithelium was separated from the underlying connective tissue with
a surgical technique and the delipidized membrane was allowed to equilibrate for ap-
proximately one hour in receptor buffer to regain lost elasticity.
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(mg)HPMC K4M HPMC K15M Carbopol
BC1 (1:1) 6.25 6.25 – – 105.10 2.40
BC2 (1:2) 6.25 12.50 – – 98.85 2.40
BC3 (1:3) 6.25 18.75 – – 92.60 2.40
BC4 (1:4) 6.25 25.00 – – 86.35 2.40
BC5 (1:5) 6.25 31.25 – – 80.10 2.40
BD1 (1:1) 6.25 – 6.25 – 105.10 2.40
BD2 (1:2) 6.25 – 12.50 – 98.85 2.40
BD3 (1:3) 6.25 – 18.75 – 92.60 2.40
BD4 (1:4) 6.25 – 25.00 – 86.35 2.40
BD5 (1:5) 6.25 – 31.25 – 80.10 2.40
BE1 (1:0.25) 6.25 – – 1.562 109.788 2.40
BE2 (1:0.50) 6.25 – – 3.125 108.225 2.40
BE3 (1:0.75) 6.25 – – 4.687 106.663 2.40
BE4 (1:1.00) 6.25 – – 6.250 105.110 2.40
BE5 (1:1.50) 6.25 – – 9.375 101.975 2.40
SSF – sodium stearyl fumarate
In vitro bioadhesion studies
The bioadhesive strength of the tablets was measured using the Ultra test (Mecmes-
in, UK) equipped with a 5 kg load cell. The fresh porcine buccal mucosa obtained from
the slaughterhouse and stored in simulated saliva solution (16.8 mmol L–1 of Na2HPO4,
1.4 mmol L–1 of KH2PO4 and 136.8 mmol L–1 of NaCl pH 6.75) was secured tightly to a
circular stainless steel adaptor (diameter 2.2 cm) provided with the necessary equip-
ment. A backup membrane was placed over the buccal tablet to be tested and fixed with
the help of cyonoacrylate adhesive to the cylindrical stainless steel adaptor of similar di-
ameter. The entire setup was mounted onto the platform of a motorized test stand. All
measurements were conducted at room temperature. During measurement, 100 mL of
1% mucin solution (crude mucin procured from Sigma Chemical Co, USA) was used to
moisten the porcine buccal membrane. The upper support was lowered at a speed of 0.5
mm s–1 until contact was made with the tissue at the predetermined force of 0.5 N for a
contact time of 180 s. At the end of contact time, the upper support was withdrawn at a
speed of 0.5 mm s–1 to detach the membrane from the tablet.
Data collection and calculations were performed using the data plot software pack-
age of the instrument. Two parameters, namely the work of adhesion and peak detach-
ment force, were used to study the buccal adhesiveness of tablets (15).
Moisture absorption
Moisture absorption study was performed according to the modified procedure re-
ported earlier (16). Agar (5%, m/V) was dissolved in hot water. It was transferred into
Petri dishes and allowed to solidify. Six buccal tablets from each formulation were plac-
ed in a vacuum oven overnight prior to the study to remove moisture, if any, and lami-
nated on one side with a water impermeable backing membrane. They were then placed
on the surface of the agar and incubated at 37 °C for one hour. Then the tablets were re-
moved and weighed and the percentage of moisture absorption was calculated.
In vitro drug permeation through porcine buccal membrane
In vitro permeation of carvedilol from matrix tablets through the porcine buccal mem-
brane was studied. The membrane was mounted over a Franz diffusion cell of i.d. 2.1
cm and the selected matrix tablet (BC3) containing 6.25 mg of carvedilol was placed on
the membrane. A dialysis membrane (HiMedia, India) with molecular mass cut off 5000
was placed over it to prevent the tablet from getting dislodged. The receiver compart-
ment of the diffusion cell was filled with 12.0 mL of alcohol : propylene glycol : phosphate
buffer saline pH 7.4 mixture (40:15:45).
The entire setup was placed over a magnetic stirrer and the temperature was main-
tained at 37 °C by placing the diffusion cell in a water bath. One mL samples were col-
lected at predetermined time intervals from the receptor compartment and replaced with
an equal volume of the above mixture. The amount of carvedilol in the diffusion sam-
ples was estimated by the HPLC method.
188
V. V. Yamsani et al.: Development and in vitro evaluation of buccoadhesive carvedilol tablets, Acta Pharm. 57 (2007) 185–197.
HPLC analysis
Analysis of samples was performed using a Shimadzu HPLC system equipped with
an LC-10AT pump (Shimadzu), RF10AXL spectrofluorimetric detector and a RP C18 Phe-
nomenex column (250 x 4.6 mm i.d., particle size 5 mm) at ambient temperature. The mo-
bile phase was a mixture of acetonitrile, methanol, water and triethylamine (25:20:54.9:0.1,
V/V). The pH was adjusted to 2.5 with orthophosphoric acid. The flow rate was 1 mL
per minute. The detection was carried on at 285 and 380 nm as excitation and emission
wavelengths respectively.
A calibration curve was plotted for carvedilol in the range of 50–500 ng mL–1. A
good linear relationship was observed between the concentration of carvedilol and its
peak area (R2 = 0.999). Precision and accuracy of the HPLC method were estimated (13).
Spectroscopic and diffraction characterization
The buccoadhesive tablets (BC3) were compressed and powdered. The pelletized
powder, along with KBr, was used for FTIR studies. The IR spectra were recorded using
an IR-spectrophotometer (Perkin Elmer FT-IR, Perkin Elmer, USA). A powder X-ray dif-
fractometer (Siemen’s D-5000, Germany) was used for diffraction studies. PXRD studies
were performed on the samples by exposing them to CuKa radiation (40 kV, 30 mA) and
scanned from 2 to 70°, at a step size of 0.045 2q and step time of 0.5 s.
RESULTS AND DISCUSSION
Our previous report showed that 75.3% of carvedilol penetrated through the por-
cine buccal epithelium in 3 h and 60.2% of the drug was absorbed from buccal patches in
16 min through the buccal cavity in healthy human volunteers (13).
Mass, thickness and drug uniformity
The mass and the thickness of the tablets (Table II) were within the limits of unifor-
mity. The mass ranged from 119.2 to 122.3 mg with RSD values 0.7–1.2%. Thickness rang-
ed between 1.74 and 2.00 mm with RSDs of 0.5 to 1.2%. The drug content ranged from
96.7 ± 0.4% in formulation BC1 to 101.4 ± 0.3% in formulation BC5, 97.0 ± 0.8% in formu-
lation BD1 to 103.2 ± 3.0 in formulation BD5 and 98.5 ± 0.9% in formulation BE1 to 102.4
± 1.7% in formulation BE4.
In vitro drug release studies
The release of carvedilol from buccoadhesive tablets (Figs. 1a–c) varied according to
the type and ratio of matrix forming polymers. The drug release was governed by the
amount of matrix forming polymer. Burst release was observed in formulations BC1 and
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BD1. The concentration of HPMC K4M and HPMC K15M was the lowest in BC1 and
BD1 among all within the series. The most important factor affecting the rate of release
from the buccal tablets is the drug : polymer ratio. An increase in polymer concentration
causes an increase in the viscosity of the gel as well as formation of a gel layer with a
longer diffusional path. This could cause a decrease in the effective diffusion coefficient
of the drug and therefore a reduction in the drug release rate. In the present study, the
results followed this predictable behaviour (Fig. 1a–c). Buccal tablets that contained low-
er concentrations of either HPMC K4M, HPMC K15M or Carbopol 934 in BC, BD and BE
series, respectively, tended to release the drug in shorter time periods, while the release
slowed down as the concentration of the gelling polymer increased, thus confirming the
dominant role of the swellable hydrophilic polymer in the release of carvedilol from
buccal tablets.
Data of the in vitro release was fit into different equations and kinetic models to ex-
plain the release kinetics of carvedilol from buccal tablets. The kinetic models (17, 18)
used were zero-order equation, first-order equation, Higuchi and Korsemeyer-Peppas
models. Formulations with HPMC K4M (BC1, BC2, BC3) (correlation coefficient betwe-
en 0.800 and 0.980) and HPMC K15M (BD1, BD2, BD3) (correlation coefficient between
0.844 and 0.985) followed the Higuchi model whereas formulations BC4, BC5 (correla-
tion coefficient 0.985 and 1.000), BD4 and BD5 (correlation coefficient 0.998 and 0.999)
followed zero-order release. In the case of Carbopol 934, BE series BE1, BE2 and BE5
(correlation coefficient between 0.961 and 0.981) followed the Higuchi model; BE3 and
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Table II. Mass, thickness and drug content
Formulation Mass (mg)a Thickness (mm)a Assay (%)b
BC1 121.5 ± 1.2 1.74 ± 0.02 96.7 ± 0.4
BC2 120.5 ± 1.8 1.86 ± 0.03 97.2 ± 0.5
BC3 120.0 ± 1.2 1.83 ± 0.02 99.8 ± 0.4
BC4 122.3 ± 1.5 1.82 ± 0.01 101.0 ± 2.3
BC5 120.0 ± 1.2 1.92 ± 0.01 101.4 ± 0.3
BD1 119.7 ± 1.2 1.82 ± 0.03 97.0 ± 0.8
BD2 120.0 ± 1.3 1.96 ± 0.01 97.3 ± 1.0
BD3 121.8 ± 1.9 1.98 ± 0.01 100.4 ± 0.5
BD4 119.8 ± 1.6 1.99 ± 0.01 101.2 ± 1.0
BD5 121.3 ± 1.1 2.00 ± 0.01 103.2 ± 3.0
BE1 120.0 ± 0.9 1.86 ± 0.01 98.5 ± 0.9
BE2 121.3 ± 0.6 1.82 ± 0.01 100.4 ± 1.0
BE3 119.2 ± 0.8 1.76 ± 0.02 101.3 ± 1.5
BE4 121.5 ± 0.5 1.84 ± 0.02 102.4 ± 1.7
BE5 121.7 ± 1.4 1.83 ± 0.01 99.6 ± 1.2
Mean ± SD; a n = 10, b n = 20.
BE4 (correlation coefficient 0.985 and 0.997), followed zero-order model. The results in-
dicate that as the concentration of each polymer increases in the respective series, Higuchi
diffusion mechanism turns to zero-order release profile.
Formulation BC3 (88.7 ± 0.4%) composed of 1:3 drug : HPMC K4M ratio; BD3 (84.2
± 0.3%) 1:3 drug : HPMC K15M ratio and BE3 (89.2 ± 0.3%) 1:0.75 drug : Carbopol 934
ratio showed maximum release among their respective series. Increasing the concentra-
tion of the polymer in the formulations showed a sustained effect on carvedilol release.
The rapidly hydrating polymer dominated in controlling the release of carvedilol from
the buccal tablets, as seen from the dissolution profiles and moisture absorption data.
Release rates slowed down when the concentration of HPMC K4M or HPMC K15M or
Carbopol 934 increased from 1:1 to 1:5 ratios and 1:0.25 to 1:1.50 in BC, BD and BE series,
respectively. This is because as the proportion of these polymers in the matrix increased,
there was an increase in the amount of water uptake and proportionally greater swelling
leading to a thicker gel layer. Zero-order release from swellable hydrophilic matrices oc-
curs as a result of constant diffusional pathlengths. When the thickness of the gelled
layer and thus the diffusional pathlengths remain constant, zero-order release can be ex-
pected, as seen for formulations BC4, BC5, BD4, BD5, BE3 and BE4.
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Fig. 1. Drug release profile of carvedilol buc-
cal tablets formulated with: a) HPMC K4M,
b) HPMC K15M and c) Carbopol 934 (mean
± SD, n = 6).
In vitro bioadhesion studies
The results of the peak detachment force and bioadhesion strength of carvedilol
buccal tablets are given in Table III. The peak detachment force and work of adhesion
for formulation BC3 were 1.62 ± 0.15 N and 0.24 ± 0.11 mJ. In all the formulations, as the
polymer concentration increased, both the peak detachment force and work of adhesion
increased. The order of bioadhesion was HPMC K4M < HPMC K15M < Carbopol. Buc-
cal tablets formulated with Carbopol 934 and HPMC K15M showed stronger mucoad-
hesion than HPMC K4M formulations. Very strong bioadhesion could damage the epi-
thelial lining of the buccal mucosa.
Moisture absorption
The moisture absorption studies give an indication of the relative moisture absorp-
tion capacities of polymers and whether the formulations maintain their integrity after
moisture absorption. The order of increasing moisture absorption was HPMC K4M <
HPMC K15M < Carbopol 934 (Table III). This may be due to the more hydrophilic nature
of the polymer Carbopol.
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Table III. Peak detachment force, bioadhesion and moisture absorption studies
Formulation Peak detachment force (N)a Work of adhesion (mJ)a Moisture absorbed (%)b
BC1 0.81± 0.01 0.09 ± 0.01 31.2 ± 1.0
BC2 1.29 ± 0.09 0.12 ± 0.03 31.3 ± 3.1
BC3 1.62 ± 0.15 0.24 ± 0.11 31.7 ± 1.4
BC4 2.08 ± 0.18 0.33 ± 0.05 33.1 ± 1.2
BC5 2.50 ± 0.20 0.43 ± 0.12 45.5 ± 2.9
BD1 0.92 ± 0.10 0.23 ± 0.11 31.5 ± 0.9
BD2 1.64 ± 0.21 0.35 ± 0.09 32.7 ± 2.6
BD3 2.03 ± 0.30 0.47 ± 0.05 36.8 ± 1.6
BD4 3.00 ± 0.42 0.98 ± 0.10 44.3 ± 3.9
BD5 3.85 ± 0.17 1.02 ± 0.13 48.4 ± 2.8
BE1 2.00 ± 0.11 1.00 ± 0.13 36.2 ± 1.5
BE2 2.50 ± 0.35 1.85 ± 0.35 53.3 ± 5.0
BE3 3.00 ± 0.41 2.25 ± 0.43 68.2 ± 1.3
BE4 4.25 ± 0.40 3.50 ± 0.51 68.6 ± 3.2
BE5 6.00 ± 0.47 4.25 ± 0.40 70.7 ± 3.3
Mean ± SD; an = 3, bn = 6.
In vitro drug permeation
Based on the in vitro drug release and bioadhesion strengths of all formulations, the
BC3 formulation was selected for in vitro permeation studies. The oral mucosa of pigs
resembles that of humans more closely than any other animal in terms of structure and
composition (19, 20) and therefore porcine buccal mucosa was selected for drug perme-
ation studies. The results of drug permeation from buccal tablets through the porcine
buccal mucosa reveal that carvedilol was released from the formulation and permeated
through the porcine buccal membrane and could possibly permeate through the human
buccal membrane. The drug permeation was slow and steady (Fig. 2) and 21.5 ± 2.9% of
carvedilol could permeate through the buccal membrane in 12 hours with a flux of 8.35
± 0.29 µg h–1cm–2 (permeation coefficient 1.34 ± 0.05 cm h–1).
Spectroscopic characterization
Figs 3a–c show IR spectra of the carvedilol, HPMC K4M and buccal tablets (BC3).
Carvedilol alone showed principal peaks of 2923.68, 1449.96, 1340.13, and 1097.31 cm–1.
The main peaks of the physical mixture and buccal tablets with HPMC K4M were 2924.95,
1451.18, 1339.71 cm–1, and 1097.31 and 2933.10, 1459.17, 1334.32 and 1059.89 cm–1, resp.
However, some additional peaks were observed with the physical mixture, which could
be due to the presence of the polymer. These results suggest that no interaction took place
between the drug and the polymer.
The X-ray powder diffraction pattern having major peaks at about 2q 4.17, 4.48, 4.74,
5.51 and 6.51 in both the drug and carvedilol buccal tablet (BC3) suggests that the drug
in the buccal tablet is not undergoing any polymorphic transitions (see Figs. 4a–c).
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Fig. 2. In vitro permeation of carvedilol from buccal tablets
through porcine buccal mucosa (mean ± SD, n = 3).
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HPMC K4M shows satisfactory buccoadhesive properties. Formulation BC3 using
this polymer in a drug : polymer (1:3) ratio showed significant bioadhesive properties with
an optimum release profile and could be useful for buccal administration of carvedilol.
Further work is recommended to support its efficacy claims by long term pharmacoki-
netic and pharmacodynamic studies in human beings.
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S A @ E T A K
Priprava i in vitro vrednovanje bukoadhezivnih tableta karvedilola
VAMSHI VISHNU YAMSANI, RAMESH GANNU, CHANDRASEKHAR KOLLI, M. E. BHANOJI RAO
i MADHUSUDAN RAO YAMSANI
Variraju}i koncentracije bukoadhezivnih polimera HPMC K4M, HPMC K15M i Car-
bopol 934 pripravljeno je 15 tableta karvedilola. Pripravci iz serije BC ili BD izra|eni su
iz karvedilola i HPMC K4 M ili HPMC K15M u omjerima 1:1, 1:2, 1:3, 1:4 i 1:5, a pri-
pravci iz BE serije iz karvedilola i Carbopol 934 u omjerima 1:0.25, 1:0.50, 1:0.75, 1:1.00 i
1:1.50. In vitro je ispitivana brzina osloba|anja ljekovite tvari, bioadhezija, apsorpcija vlage
i permeacija kroz bukalnu membranu svinje. Iz pripravka BC3 postignuto je maksimal-
no osloba|anje (88,7 ± 0,4%) koje je slijedilo Higuchijev model i maksimalna permeacija
21,5 ± 2,9% (fluks 8,35 ± 0,291 µg h–1 cm–2; permeacijski koeficijent 1,34 ± 0,05 cm h–1).
Sila odvajanja za taj pripravak bila je 1,62 ± 0,15 N, a adhezija 0,24 ± 0,11 mJ. FTIR ispi-
tivanja su pokazala da nije bilo interakcija izme|u ljekovite tvari i polimera, a XRD ispi-
tivanja da je ljekovita tvar u kristalini~noj formi u polimernom matriksu. Pripravljene
bukalne tablete su dovoljno bioadhezivne, a permeacija iz njih je zadovoljavaju}a.
Klju~ne rije~i: bukalne tablete, karvedilol, bioadhezija, vrednovanje
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